FI86634B - Foerfarande foer framstaellning av farmakologiskt aktiva 2-hydroxipyrid-6-ylsubstituerade amidiner. - Google Patents

Foerfarande foer framstaellning av farmakologiskt aktiva 2-hydroxipyrid-6-ylsubstituerade amidiner. Download PDF

Info

Publication number
FI86634B
FI86634B FI871126A FI871126A FI86634B FI 86634 B FI86634 B FI 86634B FI 871126 A FI871126 A FI 871126A FI 871126 A FI871126 A FI 871126A FI 86634 B FI86634 B FI 86634B
Authority
FI
Finland
Prior art keywords
formula
alkyl
compounds
mmol
compound
Prior art date
Application number
FI871126A
Other languages
English (en)
Finnish (fi)
Other versions
FI871126A0 (fi
FI871126A (fi
FI86634C (sv
Inventor
Sprecher Georg Von
Peter Waldmeier
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of FI871126A0 publication Critical patent/FI871126A0/fi
Publication of FI871126A publication Critical patent/FI871126A/fi
Publication of FI86634B publication Critical patent/FI86634B/fi
Application granted granted Critical
Publication of FI86634C publication Critical patent/FI86634C/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Claims (4)

1. Förfarande för framställning av farmakologiskt aktiva 2-hydroxipyrid-6-ylsubstituerade amidiner med formeln I X· E] β-2 ! f/ ( I ) </ ^ XR3 eller deras tautomerer och/eller salter, i vilken formel Rj betecknar väte eller C^-C^-alkyl, en av resterna R2 och R3 betecknar väte eller C1-C7-alkyl och den andra betecknar Cj-Gj-alkyl eller fenyl-Cj-C^-alkyl och R4 betecknar väte, Ci-Gy-alkyl eller fenyl-Cj-C7-alkyl, känne-t e c k n a t därav, att a) en förening med formeln Ila S\ } "-NH-X, (Ila) ^ ί eller en tautomer därav omsätts med en förening med formeln Hb /Rz X2 - N (Hb) ^R3 33 8<^34 varvid en av resterna Xx och X2 betecknar en grupp med formeln -CO-Rx och den andra är väte, eller en tautomer, ett sait och/eller en acetal därav, eller b) i en förening med formeln III Λ „ f· ^'x(I1I) eller i en tautomer och/eller ett sait därav, i vilken X3 betecknar Cj-Gj-alkoxi, X3 omvandlas tili en grupp -N genom att omsätta med en amin med formeln \r3 /R2 H-N (Ile) eller c) för framställning av föreningar med formeln I eller tautomerer och/eller salter därav, i vilka R4 betecknar väte, i en förening med formeln IV i Γι /Rz <IV) eller ett sait därav, i vilken formel X4 betecknar Cj-C^-alkoxi, X4 omvandlas genom aeidolys tili hydroxi, eller d) en förening med formeln Va /\ o/y''-x‘ 34 86634 eller en tautomer eller ett salt därav omsätts med en förening med formeln X7 - N (Vb) eller en tautomer eller ett sait därav, varvid antingen X6 betecknar en grupp -N=CR1-NH-X5 och X7 betecknar väte eller X6 betecknar en grupp -NH2 och X7 betecknar en grupp -CRj=N-X5 och X5 betecknar cyano, och, om sä önskas, en i varje enskilt fall enligt förfa-randet eller pä nägot annat sätt erhällen förening med formeln I eller en tautomer därav omvandlas tili en annan förening med formeln I eller en tautomer därav, och/eller en enligt förfarandet erhällen fri förening eller en tautomer därav omvandlas tili ett sait eller ett enligt förfarandet erhället sait omvandlas tili en fri förening med formeln I eller en tautomer därav eller ett annat sait.
2. Förfarande enligt patentkravet 1 för framställning av föreningar med formeln I eller tautomerer och/eller sal-ter därav, kännetecknat därav, att Ri betecknar väte eller C^-C^-alkyl, en av resterna R2 och R3 betecknar väte eller C^-C^-alkyl och den andra betecknar C7-C7-alkyl eller fenyl-C^-Gj-alkyl och R4 betecknar väte eller Cj-Gy-alkyl.
3. Förfarande enligt patentkravet 1 för framställning av föreningar med formeln I eller tautomerer och/eller sal-ter därav, kännetecknat därav, att R3 betecknar väte eller C,-C7-alkyl, en av resterna R2 och R3 betecknar väte eller Cj-C7-alkyl och den andra Cj-C^-alkyl eller fenyl-C1-C7-alkyl och R4 betecknar väte. 86634 35
4. Förfarande enligt nägot av patentkraven 1-3, k ä n -netecknat därav, att man framställer N-(2-hydro-xi-6-pyridyl)-N',N'-dl-(n-propyl)-formamidin eller resp. N-(2-pyridon-6-yl)-N',N'-di-(n-propyl)-formamidin eller ett sait därav.
FI871126A 1986-03-17 1987-03-13 Förfarande för framställning av farmakologiskt aktiva 2-hydroxipyrid-6 -ylsubstituerade amidiner FI86634C (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH108486 1986-03-17
CH108486 1986-03-17
CH226986 1986-06-04
CH226986 1986-06-04

Publications (4)

Publication Number Publication Date
FI871126A0 FI871126A0 (fi) 1987-03-13
FI871126A FI871126A (fi) 1987-09-18
FI86634B true FI86634B (fi) 1992-06-15
FI86634C FI86634C (sv) 1992-09-25

Family

ID=25686601

Family Applications (1)

Application Number Title Priority Date Filing Date
FI871126A FI86634C (sv) 1986-03-17 1987-03-13 Förfarande för framställning av farmakologiskt aktiva 2-hydroxipyrid-6 -ylsubstituerade amidiner

Country Status (18)

Country Link
US (1) US4863938A (sv)
EP (1) EP0239533B1 (sv)
JP (1) JPH0662566B2 (sv)
KR (1) KR910000658B1 (sv)
AU (1) AU601401B2 (sv)
CA (1) CA1312869C (sv)
DE (1) DE3781705D1 (sv)
DK (1) DK170334B1 (sv)
ES (1) ES2052601T3 (sv)
FI (1) FI86634C (sv)
GR (1) GR3006476T3 (sv)
HU (1) HU201913B (sv)
IE (1) IE59812B1 (sv)
IL (1) IL81903A0 (sv)
NO (1) NO172984C (sv)
NZ (1) NZ219629A (sv)
PH (1) PH25903A (sv)
PT (1) PT84490B (sv)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3073851A (en) * 1957-12-04 1963-01-15 Hoffmann La Roche Formamidines of primary amines
NL253634A (sv) * 1959-07-10
US3184482A (en) * 1961-11-20 1965-05-18 Hoffmann La Roche Anthraquinone formamidines of primary amines
US3182053A (en) * 1961-11-20 1965-05-04 Hoffmann La Roche Pyridine formamidines of primary amines
US3133078A (en) * 1961-11-20 1964-05-12 Hoffmann La Roche Oxazole formamidines of primary amines
GB1256714A (sv) * 1968-06-27 1971-12-15
US4186264A (en) * 1976-04-20 1980-01-29 Pfizer Inc. Triazapentadienes as acaricides
US4128652A (en) * 1976-04-20 1978-12-05 Pfizer Inc. Triazapentadienes as acaricides

Also Published As

Publication number Publication date
JPH0662566B2 (ja) 1994-08-17
CA1312869C (en) 1993-01-19
US4863938A (en) 1989-09-05
PH25903A (en) 1991-12-19
IE870687L (en) 1987-09-17
NO871075D0 (no) 1987-03-16
NZ219629A (en) 1990-03-27
AU601401B2 (en) 1990-09-13
DK133687D0 (da) 1987-03-16
NO172984C (no) 1993-10-06
PT84490A (en) 1987-04-01
PT84490B (pt) 1989-11-10
ES2052601T3 (es) 1994-07-16
HUT43823A (en) 1987-12-28
JPS62226959A (ja) 1987-10-05
NO871075L (no) 1987-09-18
FI871126A0 (fi) 1987-03-13
DK133687A (da) 1987-09-18
DK170334B1 (da) 1995-08-07
FI871126A (fi) 1987-09-18
EP0239533A1 (de) 1987-09-30
KR910000658B1 (ko) 1991-01-31
KR870008850A (ko) 1987-10-21
FI86634C (sv) 1992-09-25
NO172984B (no) 1993-06-28
IE59812B1 (en) 1994-04-06
HU201913B (en) 1991-01-28
DE3781705D1 (de) 1992-10-22
IL81903A0 (en) 1987-10-20
EP0239533B1 (de) 1992-09-16
GR3006476T3 (sv) 1993-06-21
AU7007087A (en) 1987-09-24

Similar Documents

Publication Publication Date Title
KR0142417B1 (ko) 3급알킬작용성화된피레라진유도체
FI93832C (sv) Förfarande för framställning av terapeutiskt aktiva piperazinderivat
US4438035A (en) Method of preparing benzothiazepine derivatives
FI80019C (sv) Förfarande för framställning av terapeutiskt användbara N-(piperidinyl -alkyl)karboxamider
US5872115A (en) 2-ureido-benzamide derivatives
AU600376B2 (en) N-aminobutyl-n-phenylarylamide derivatives, their preparation and their application in therapy
IL98029A (en) Guanidine analogues, their preparation process and pharmaceutical preparations containing them
JPS59118765A (ja) ピペラジン誘導体
US5300646A (en) Heterocyclic amine derivatives, their production and use
FI86545C (sv) Förfarande för framställning av terapeutiskt verkande 1-aroyl-4-aralky lpiperaziner
FI107916B (sv) Förfarande för framställning av hydrazonderivat
US5504098A (en) Benzothiazolesulfonamide derivative, method for preparing the same, and use thereof
FI86634B (fi) Foerfarande foer framstaellning av farmakologiskt aktiva 2-hydroxipyrid-6-ylsubstituerade amidiner.
EP0229370B1 (en) Guanidinobenzoic ester derivative, a process for preparing same and pharmaceutical compositions containing same
US20030195219A1 (en) Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering cns activity
EP0366006B1 (en) Pyridylketoxime ether compound and pharmaceutical composition containing it
US3121074A (en) Nitro substituted jh-l
JPS6055503B2 (ja) 新規置換ベンズアミド，その製造法およびこれを有効成分とする鎮吐剤
US3933836A (en) Pyridinylidene guanidines
IL26416A (en) History of 6,5 - Dihydro - Divance - [e, b] - Azpine-6, 11 - 11 - Basic-transformed oxen
IE61880B1 (en) 2-Aminoacetamide pyridinyl derivatives
RU2827339C1 (ru) Способ получения фонтурацетама из фенибута
EP0412529A1 (en) Imidazole derivatives, process for the preparation of the same and antiulcer agents containing the same
HU204795B (en) Process for producing calcium antagonist cyclic quanidine derivatives and pharmaceutical compositions comprising same
KR800001218B1 (ko) 티아졸리닐 케로벤즈아미다졸 및 이의 유도체의 제조방법

Legal Events

Date Code Title Description
MM Patent lapsed
MM Patent lapsed

Owner name: CIBA-GEIGY AG